Saturday, 12 March 2022

Moderna doses first subject in Omicron-specific booster vaccine trial: This booster merges the company’s Covid-19 vaccine, mRNA-1273, and an Omicron-specific booster candidate, mRNA-1273.529.

Moderna doses first subject in Omicron-specific booster vaccine trial: This booster merges the company’s Covid-19 vaccine, mRNA-1273, and an Omicron-specific booster candidate, mRNA-1273.529. submitted by /u/shallah
[link] [comments]


from Health https://ift.tt/s0IYgxc
via IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)